POCUS: Predicting Outcomes for Covid-19 Using Sonography
Study Details
Study Description
Brief Summary
This study seeks to investigate the role of lung ultrasound in caring for Covid-19 positive patients and whether it can be used to predict patient deterioration. This information will be vital for healthcare workers who seek to identify Covid-19 pneumonia or patients at risk for deterioration early in the disease course.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
As Covid-19 continues to stress hospital-based resources (including personal protective equipment, ancillary staff availability, and imaging study utilization), it is important to assess whether alternative methods for evaluating patients can be utilized to appropriately triage and care for Covid-positive patients. Current limitations of caring for patients with Covid-19 include the exposure of ancillary healthcare workers (including radiological technicians) and the time/resources required to decontaminate traditional radiological equipment such as x-ray or computerized tomography (CT) machines.
Point-of-care ultrasound (POCUS) has the potential to transform healthcare delivery due to its diagnostic and therapeutic expediency. It can be quickly performed at the bedside by experienced clinicians. It it has been shown to reliably and accurately diagnose patients with a variety of lung diseases, including pneumonia. This study seeks to investigate the role of lung ultrasound in caring for Covid-19 positive patients and whether it can be used to predict patient deterioration. This information will be vital for healthcare workers who seek to identify the virus or patients at risk for deterioration early in the disease course. Moreover, it has the potential to reduce the need for x-rays or CTs for Covid-19 patients, which has the potential to alleviate a significant burden currently being placed on the healthcare system.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Covid-19 Positive Patients This group includes individuals who were diagnosed with Covid-19 based on reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharynx |
Diagnostic Test: Lung Ultrasound
Lung ultrasound will be performed on patients undergoing investigation for covid-19 based on a nasopharyngeal PCR.
|
Covid-19 Negative Patients This group includes individuals who did NOT have a positive test for Covid-19 based on reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharynx. |
Diagnostic Test: Lung Ultrasound
Lung ultrasound will be performed on patients undergoing investigation for covid-19 based on a nasopharyngeal PCR.
|
Outcome Measures
Primary Outcome Measures
- Number of Patients Experiencing Death, ICU Admission, Mechanical Ventilation, or Use of High-Flow Nasal Cannula [28 days from initial evaluation]
Composite primary outcome of death, ICU admission, mechanical ventilation, or use of high-flow nasal cannula (categorical)
Secondary Outcome Measures
- Number of Patients Requiring Mechanical Ventilation [28 days from initial evaluation]
- Number of Patients Requiring Supplemental Oxygen Usage [28 days from initial evaluation]
- Duration of Supplemental Oxygen Usage [28 days from initial evaluation]
- Length of Stay [28 days from initial evaluation]
Duration of Hospitalization (days)
- Characterization of Ultrasound Findings [28 days from initial evaluation]
Descriptive analysis of ultrasound findings in Covid-19
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Any adult (18 or more years of age) presenting to the emergency department with symptoms suspicious for Covid-19
-
This individual underwent evaluation for Covid-19 via a nasopharyngeal RT-PCR
-
This individual received a lung ultrasound by the study authors within 28 days from initial evaluation
Exclusion Criteria:
- Any individual who did not receive a lung ultrasound within 28 days from initial evaluation for covid-19 related illness
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of California San Francisco | San Francisco | California | United States | 94117 |
2 | Stanford University | Stanford | California | United States | 95401 |
Sponsors and Collaborators
- Stanford University
Investigators
- Principal Investigator: Andre D Kumar, MD, MEd, Stanford University
- Principal Investigator: Sally Graglia, MD, MPH, University of California, San Francisco
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB-55621